Home » LABCORP ADVANCES LEADERSHIP POSITION IN DRUG METABOLISM TESTING
LABCORP ADVANCES LEADERSHIP POSITION IN DRUG METABOLISM TESTING
Laboratory Corporation of America Holdings (LabCorp) , a national leader in pharmacogenetic testing, today announced that it has begun offering a personalized drug response interpretation service for cytochrome P450 (CYP450) testing called Signature Genetics to complement its expanding menu of genetic tests for CYP450 mutations.
Finanzen.net
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May